EP Patent

EP4143182B1 — Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors

Assigned to Rhizen Pharmaceuticals AG · Expires 2024-12-11 · 1y expired

What this patent protects

Patent listed against rucaparib-camsylate.

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: EP4143182B1
Jurisdiction: EP
Classification: —
Expires: 2024-12-11
Drug substance claim: No
Drug product claim: No
Assignee: Rhizen Pharmaceuticals AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.